Evogene Ltd.
EVGN
$0.59
-$0.01-1.39%
NASDAQ
| 12/31/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 6.51M | 3.73M | 5.58M | 5.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 6.51M | 3.73M | 5.58M | 5.72M |
| Cost of Revenue | -- | 3.39M | 3.59M | 2.38M | 1.66M |
| Gross Profit | -- | 3.12M | 143.00K | 3.20M | 4.06M |
| SG&A Expenses | -- | 8.02M | 7.90M | 8.98M | 10.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -3.50M |
| Total Operating Expenses | -- | 22.19M | 21.67M | 23.87M | 28.38M |
| Operating Income | -- | -15.68M | -17.94M | -18.29M | -22.66M |
| Income Before Tax | -- | -12.34M | -12.87M | -14.81M | -22.42M |
| Income Tax Expenses | -- | 9.00K | 8.00K | 8.00K | 16.00K |
| Earnings from Continuing Operations | -- | -12.35 | -12.88 | -14.82 | -22.44 |
| Earnings from Discontinued Operations | -- | -3.55M | -3.55M | -2.46M | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 1.64M | 1.99M | 1.57M | 2.16M |
| Net Income | -- | -14.25M | -15.21M | -16.49M | -20.28M |
| EBIT | -- | -15.68M | -17.94M | -18.29M | -22.66M |
| EBITDA | -- | -15.22M | -17.72M | -17.71M | -20.07M |
| EPS Basic | -- | -2.03 | -2.48 | -2.86 | -4.74 |
| Normalized Basic EPS | -- | -0.27 | -- | -- | -1.75 |
| EPS Diluted | -- | -2.03 | -2.48 | -2.86 | -4.74 |
| Normalized Diluted EPS | -- | -0.27 | -- | -- | -1.75 |
| Average Basic Shares Outstanding | -- | 25.53M | 23.39M | 21.67M | 17.33M |
| Average Diluted Shares Outstanding | -- | 25.53M | 23.39M | 21.67M | 17.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |